IMMU-38. PRECLINICAL VALIDATION AND MANUFACTURE OF IL-8 RECEPTOR-MODIFIED CD70 CAR T CELLS FOR CLINICAL TRIAL

BACKGROUND: Chimeric antigen receptor (CAR) modified T cell therapy is a promising treatment strategy for cancer therapy. We developed IL-8 receptor-linked CD70CAR (8R-70CAR), aiming to enhance T-cell intratumoral trafficking and persistence, guided by IL-8-secreting tumors. The preclinical results...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Jin, Linchun, Tao, Haipeng, Na, Meng, Karachi, Aida, Mendez-Gomez, Hector, Weidert, Frances, Hou, Alicia, Sayour, Elias, Mitchell, Duane, Huang, Jianping
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651229/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.468
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados